Nitzan Rosenfeld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nitzan Rosenfeld has a total of 364 co-authors. Here are the top co-authors by number of shared publications:
- Florent Mouliere
Cancer Research UK National Biomarker Centre, University of Manchester, Manchester, UK
17 shared publications James Morris
Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
14 shared publications- Dineika Chandrananda
Peter MacCallum Cancer Centre, Melbourne, Australia
11 shared publications Davina Gale
Cancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Cambridge CB2 0RE, United Kingdom
10 shared publications- Wendy N. Cooper
Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, London, UK
10 shared publications - Katrin Heider
Cancer Research UK Cambridge Institute, University of Cambridge
9 shared publications
Latest Publications
- Open Access
- 3 August 2026
- Published by Springer Nature in BJC Reports
- Vol. 4 (1) , 40
Outcomes from the NHS-Galleri trial: the good, the bad, and the uncertain
- 3 August 2026
- Published by Springer Nature in BJC Reports
- Vol. 4 (1) , 40
Open AccessOutcomes from the NHS-Galleri trial: the good, the bad, and the uncertain
- Open Access
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eady9432
A scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing
Cell-free DNA (cfDNA) in body fluids enables noninvasive cancer detection. Multifeature artificial intelligence (AI) can improve sensitivity by integrating diverse biomarkers when cancer signals are sparse. Tumor-informed assays that rely on mutations have limited practicality for early cancer detection. Emerging fragmentomic and epigenetic features underpin tumor-naive approaches to screening for individuals with low tumor burden. Here, we designed UNITE—a universal cfDNA feature ensemble framework that provides scalable cancer detection methods based on “genomic bin–fragment length” matrices derived from shallow whole-genome sequencing (sWGS) data at 0.1× depth. Using sWGS data from 2063 plasma samples (631 controls and 1432 cases from 26 cancer types), we systematically evaluated both XGBoost (UNITE-XGB) and convolutional neural networks (UNITE-CNN) across multiple feature spaces and cancer stages. In stage I-II cancer, UNITE-XGB and UNITE-CNN achieved 31 and 21% sensitivity, respectively, at 95% specificity. These findings provide roadmaps for developing multifeature AI beyond plasma biopsies.
- 10 July 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (28) , eady9432
Open AccessA scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing
Cell-free DNA (cfDNA) in body fluids enables noninvasive cancer detection. Multifeature artificial intelligence (AI) can improve sensitivity by integrating diverse biomarkers when cancer signals are sparse. Tumor-informed assays that rely on mutations have limited practicality for early cancer detection. Emerging fragmentomic and epigenetic features underpin tumor-naive approaches to screening for individuals with low tumor burden. Here, we designed UNITE—a universal cfDNA feature ensemble framework that provides scalable cancer detection methods based on “genomic bin–fragment length” matrices derived from shallow whole-genome sequencing (sWGS) data at 0.1× depth. Using sWGS data from 2063 plasma samples (631 controls and 1432 cases from 26 cancer types), we systematically evaluated both XGBoost (UNITE-XGB) and convolutional neural networks (UNITE-CNN) across multiple feature spaces and cancer stages. In stage I-II cancer, UNITE-XGB and UNITE-CNN achieved 31 and 21% sensitivity, respectively, at 95% specificity. These findings provide roadmaps for developing multifeature AI beyond plasma biopsies.
- Open Access
- 8 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Cell-free DNA size deconvolution resolves nucleosomal origins and reveals tumor-associated fragmentomic alterations
Analysis of cell-free DNA (cfDNA) fragmentomic features holds great promise for minimally invasive cancer diagnostics. Although selectively analyzing short plasma cfDNA enriches tumor-derived DNA (ctDNA), the mechanisms shaping cfDNA size profiles remain incompletely understood. Here, we develop a generalized model of cfDNA fragment length distributions across multiple bodily fluids (saliva, urine, cerebrospinal fluid, lymphatic fluid, and plasma), deconvoluting size profiles into ~10-bp periodic peaks (components), each approximated by a Cauchy–Lorentz distribution. This analytical framework enables investigation of cfDNA fragmentation across diverse pathological states and reveals a 159-bp component that may demarcate intra- and inter-nucleosomal cfDNA. By analyzing plasma DNA from individuals harboring germline TP53 mutations, patients receiving radiotherapy, and liver transplantation recipients, we demonstrate that ctDNA shortening can be distinguished from phagocytosis-associated cfDNA shortening through differences in the amplitude and scale parameters of intra- and inter-nucleosomal components. Moreover, leveraging tumor-related fragmentomic alterations, characterized by increased fragmentation entropy identified through cfDNA size deconvolution, significantly enhances cancer detection.
- 8 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessCell-free DNA size deconvolution resolves nucleosomal origins and reveals tumor-associated fragmentomic alterations
Analysis of cell-free DNA (cfDNA) fragmentomic features holds great promise for minimally invasive cancer diagnostics. Although selectively analyzing short plasma cfDNA enriches tumor-derived DNA (ctDNA), the mechanisms shaping cfDNA size profiles remain incompletely understood. Here, we develop a generalized model of cfDNA fragment length distributions across multiple bodily fluids (saliva, urine, cerebrospinal fluid, lymphatic fluid, and plasma), deconvoluting size profiles into ~10-bp periodic peaks (components), each approximated by a Cauchy–Lorentz distribution. This analytical framework enables investigation of cfDNA fragmentation across diverse pathological states and reveals a 159-bp component that may demarcate intra- and inter-nucleosomal cfDNA. By analyzing plasma DNA from individuals harboring germline TP53 mutations, patients receiving radiotherapy, and liver transplantation recipients, we demonstrate that ctDNA shortening can be distinguished from phagocytosis-associated cfDNA shortening through differences in the amplitude and scale parameters of intra- and inter-nucleosomal components. Moreover, leveraging tumor-related fragmentomic alterations, characterized by increased fragmentation entropy identified through cfDNA size deconvolution, significantly enhances cancer detection.
- Open Access
- 19 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (4) , 1429-1455
ctDNA monitoring using tumor-informed copy number analysis
Methods to detect circulating tumor DNA (ctDNA) enable minimally invasive responsive monitoring of cancer dynamics. However, sensitive and cost-effective methods are still lacking. Current methods for detecting cancer signals in shallow whole-genome sequencing (sWGS) data from cell-free DNA (cfDNA) via copy number aberration (CNA) analysis typically have a limit of detection of approximately 3% tumor fraction (TF). We developed informCNA, a bioinformatics method that leverages CNA information from sWGS of tumor or pre-treatment plasma samples with high TF as references, enabling ctDNA detection down to 0.2% TF across multiple cancer types. In 177 serial plasma samples from 18 patients with ovarian cancer, informCNA showed high concordance with the standard serum protein marker CA-125 and identified recurrence a median of 3.7 months earlier than CA-125 test. These results demonstrate the potential of personalized CNA analysis through sWGS for estimating ctDNA burden, enabling precise and cost-effective disease monitoring and early detection of relapse.
- 19 March 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (4) , 1429-1455
Open AccessctDNA monitoring using tumor-informed copy number analysis
Methods to detect circulating tumor DNA (ctDNA) enable minimally invasive responsive monitoring of cancer dynamics. However, sensitive and cost-effective methods are still lacking. Current methods for detecting cancer signals in shallow whole-genome sequencing (sWGS) data from cell-free DNA (cfDNA) via copy number aberration (CNA) analysis typically have a limit of detection of approximately 3% tumor fraction (TF). We developed informCNA, a bioinformatics method that leverages CNA information from sWGS of tumor or pre-treatment plasma samples with high TF as references, enabling ctDNA detection down to 0.2% TF across multiple cancer types. In 177 serial plasma samples from 18 patients with ovarian cancer, informCNA showed high concordance with the standard serum protein marker CA-125 and identified recurrence a median of 3.7 months earlier than CA-125 test. These results demonstrate the potential of personalized CNA analysis through sWGS for estimating ctDNA burden, enabling precise and cost-effective disease monitoring and early detection of relapse.
- Open Access
- 6 October 2025
- Published by Springer Nature in Research Square
A mathematical model of cell-free DNA fragment size reveals cancer-specific fragmentomic patterns
Analysis of cell-free DNA (cfDNA) fragmentomic features shows promise for minimally invasive cancer diagnostics. The size distribution of cfDNA molecules has emerged as a novel analytical dimension enhancing ctDNA detection. Here, we propose a mathematical model of cfDNA length distribution across multiple biodiy flulids, deconvoluted into a series of peaks (components) represented by the Cauchy–Lorentz distribution with an approximate 10 bp periodicity. This model provides a new analytical framework for investigating the biological mechanisms of cfDNA fragmentation and release, leading to the identification of a previously uncharacterized 159 bp fragment length, that may indicate a demarcation between intra- and inter-nucleosome-derived cfDNA. Furthermore, we demonstrate that tumor-specific ctDNA shortening and phagocytosis-associated cfDNA shortening can be differentiated through analysis of the amplitudes and scales of intra- and inter-nucleosomal components. Moreover, leveraging ctDNA-specific alterations revealed by cfDNA size profile deconvolution analysis could significantly enhance cancer detection.
- 6 October 2025
- Published by Springer Nature in Research Square
Open AccessA mathematical model of cell-free DNA fragment size reveals cancer-specific fragmentomic patterns
Analysis of cell-free DNA (cfDNA) fragmentomic features shows promise for minimally invasive cancer diagnostics. The size distribution of cfDNA molecules has emerged as a novel analytical dimension enhancing ctDNA detection. Here, we propose a mathematical model of cfDNA length distribution across multiple biodiy flulids, deconvoluted into a series of peaks (components) represented by the Cauchy–Lorentz distribution with an approximate 10 bp periodicity. This model provides a new analytical framework for investigating the biological mechanisms of cfDNA fragmentation and release, leading to the identification of a previously uncharacterized 159 bp fragment length, that may indicate a demarcation between intra- and inter-nucleosome-derived cfDNA. Furthermore, we demonstrate that tumor-specific ctDNA shortening and phagocytosis-associated cfDNA shortening can be differentiated through analysis of the amplitudes and scales of intra- and inter-nucleosomal components. Moreover, leveraging ctDNA-specific alterations revealed by cfDNA size profile deconvolution analysis could significantly enhance cancer detection.
- Top Cited Papers
- 13 June 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 22 (8) , 566-580
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests
Cancer screening is an essential public health intervention for diagnosing cancers at an early stage that can enable earlier treatment — ideally with curative intent — and thus lead to improved outcomes. Over the past decade, liquid biopsy-based tests have emerged as a promising, minimally invasive and broadly applicable screening approach by combining multi-cancer early detection (MCED) with tumour tissue-of-origin identification. Large-scale randomized clinical trials evaluating liquid biopsy-based MCED approaches are now under way, although whether the diagnostic performance of this first generation of MCED tests is sufficient to translate into clinical benefits remains to be determined. In this Review, we discuss the promises and pitfalls of current MCED tests and highlight possible trajectories for the field of early cancer detection.
- 13 June 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 22 (8) , 566-580
Top Cited PapersPromises and pitfalls of multi-cancer early detection using liquid biopsy tests
Cancer screening is an essential public health intervention for diagnosing cancers at an early stage that can enable earlier treatment — ideally with curative intent — and thus lead to improved outcomes. Over the past decade, liquid biopsy-based tests have emerged as a promising, minimally invasive and broadly applicable screening approach by combining multi-cancer early detection (MCED) with tumour tissue-of-origin identification. Large-scale randomized clinical trials evaluating liquid biopsy-based MCED approaches are now under way, although whether the diagnostic performance of this first generation of MCED tests is sufficient to translate into clinical benefits remains to be determined. In this Review, we discuss the promises and pitfalls of current MCED tests and highlight possible trajectories for the field of early cancer detection.
- Open Access
- 23 May 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-27
A standardized framework for robust fragmentomic feature extraction from cell-free DNA sequencing data
Fragmentomics features of cell-free DNA represent promising non-invasive biomarkers for cancer diagnosis. A lack of systematic evaluation of biases in feature quantification hinders the adoption of such applications. We compare features derived from whole-genome sequencing of ten healthy donors using nine library kits and ten data-processing routes and validated in 1182 plasma samples from published studies. Our results clarify the variations from library preparation and feature quantification methods. We design the Trim Align Pipeline and cfDNAPro R package as unified interfaces for data pre-processing, feature extraction, and visualization to standardize multi-modal feature engineering and integration for machine learning.
- 23 May 2025
- Published by Springer Nature in Genome Biology
- Vol. 26 (1) , 1-27
Open AccessA standardized framework for robust fragmentomic feature extraction from cell-free DNA sequencing data
Fragmentomics features of cell-free DNA represent promising non-invasive biomarkers for cancer diagnosis. A lack of systematic evaluation of biases in feature quantification hinders the adoption of such applications. We compare features derived from whole-genome sequencing of ten healthy donors using nine library kits and ten data-processing routes and validated in 1182 plasma samples from published studies. Our results clarify the variations from library preparation and feature quantification methods. We design the Trim Align Pipeline and cfDNAPro R package as unified interfaces for data pre-processing, feature extraction, and visualization to standardize multi-modal feature engineering and integration for machine learning.
- Top Cited PapersOpen Access
- 24 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Integrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
High grade serous ovarian carcinoma (HGSOC) is a highly heterogeneous disease that typically presents at an advanced, metastatic state. The multi-scale complexity of HGSOC is a major obstacle to predicting response to neoadjuvant chemotherapy (NACT) and understanding critical determinants of response. Here we present a framework to predict the response of HGSOC patients to NACT integrating baseline clinical, blood-based, and radiomic biomarkers extracted from all primary and metastatic lesions. We use an ensemble machine learning model trained to predict the change in total disease volume using data obtained at diagnosis (n = 72). The model is validated in an internal hold-out cohort (n = 20) and an independent external patient cohort (n = 42). In the external cohort the integrated radiomics model reduces the prediction error by 8% with respect to the clinical model, achieving an AUC of 0.78 for RECIST 1.1 classification compared to 0.47 for the clinical model. Our results emphasize the value of including radiomics data in integrative models of treatment response and provide methods for developing new biomarker-based clinical trials of NACT in HGSOC.
- 24 October 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-14
Top Cited PapersOpen AccessIntegrated radiogenomics models predict response to neoadjuvant chemotherapy in high grade serous ovarian cancer
High grade serous ovarian carcinoma (HGSOC) is a highly heterogeneous disease that typically presents at an advanced, metastatic state. The multi-scale complexity of HGSOC is a major obstacle to predicting response to neoadjuvant chemotherapy (NACT) and understanding critical determinants of response. Here we present a framework to predict the response of HGSOC patients to NACT integrating baseline clinical, blood-based, and radiomic biomarkers extracted from all primary and metastatic lesions. We use an ensemble machine learning model trained to predict the change in total disease volume using data obtained at diagnosis (n = 72). The model is validated in an internal hold-out cohort (n = 20) and an independent external patient cohort (n = 42). In the external cohort the integrated radiomics model reduces the prediction error by 8% with respect to the clinical model, achieving an AUC of 0.78 for RECIST 1.1 classification compared to 0.47 for the clinical model. Our results emphasize the value of including radiomics data in integrative models of treatment response and provide methods for developing new biomarker-based clinical trials of NACT in HGSOC.
- Open Access
- 10 May 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (6) , e16505
Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer
Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area of increasing interest. Multiple methods have been proposed but few studies have compared the performance of different approaches. Here, we compare detection of ctDNA in serial plasma samples from patients with breast cancer using different tumor‐informed and tumor‐naïve assays designed to detect structural variants (SVs), single nucleotide variants (SNVs), and/or somatic copy‐number aberrations, by multiplex PCR, hybrid capture, and different depths of whole‐genome sequencing. Our results demonstrate that the ctDNA dynamics and allele fractions (AFs) were highly concordant when analyzing the same patient samples using different assays. Tumor‐informed assays showed the highest sensitivity for detection of ctDNA at low concentrations. Hybrid capture sequencing targeting between 1,347 and 7,491 tumor‐identified mutations at high depth was the most sensitive assay, detecting ctDNA down to an AF of 0.00024% (2.4 parts per million, ppm). Multiplex PCR targeting 21–47 tumor‐identified SVs per patient detected ctDNA down to 0.00047% AF (4.7 ppm) and has potential as a clinical assay.
- 10 May 2023
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 15 (6) , e16505
Open AccessComparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer
Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area of increasing interest. Multiple methods have been proposed but few studies have compared the performance of different approaches. Here, we compare detection of ctDNA in serial plasma samples from patients with breast cancer using different tumor‐informed and tumor‐naïve assays designed to detect structural variants (SVs), single nucleotide variants (SNVs), and/or somatic copy‐number aberrations, by multiplex PCR, hybrid capture, and different depths of whole‐genome sequencing. Our results demonstrate that the ctDNA dynamics and allele fractions (AFs) were highly concordant when analyzing the same patient samples using different assays. Tumor‐informed assays showed the highest sensitivity for detection of ctDNA at low concentrations. Hybrid capture sequencing targeting between 1,347 and 7,491 tumor‐identified mutations at high depth was the most sensitive assay, detecting ctDNA down to an AF of 0.00024% (2.4 parts per million, ppm). Multiplex PCR targeting 21–47 tumor‐identified SVs per patient detected ctDNA down to 0.00047% AF (4.7 ppm) and has potential as a clinical assay.
- Open Access
- 17 January 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer
- 17 January 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1
Open AccessAuthor Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer